Posts tagged Teva Canada
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

MONTRÉAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY® (fremanezumab). AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY® was available in a prefilled syringe only. The product is now available in two latex-free1 formats: a new autoinjector and a prefilled syringe.

Read More
Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers

TORONTO, April 6, 2021 /CNW/ - Extending its ongoing commitment to caregivers through the Caregiver-Friendly Pharmacy (CFP) program, and recognizing the significant toll COVID-19 has had on the caregiver community over the past year, Teva Canada today unveiled new resources and programming to support the mental health challenges caregivers often experience.

Read More